Parallel Advisors’s ArriVent BioPharma AVBP Stock Holding History

Parallel Advisors’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$834	Hold	24	–	–	﹤0.01%	3717
2026 Q1	$554	Buy	+24	New	+$542	﹤0.01%	3652
2025 Q4	–	Sell	-82	Closed	-$1.51K	–	3769
2025 Q3	$1.51K	Hold	82	–	–	﹤0.01%	3123
2025 Q2	$1.78K	Buy	+82	New	+$1.7K	﹤0.01%	3065
2025 Q1	–	Sell	-3	Closed	-$80	–	3693
2024 Q4	$80	Buy	+3	New	+$86	﹤0.01%	3458

Other funds holding AVBP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

Parallel Advisors's AVBP Position: Q2 2026 in Review

Parallel Advisors held its ArriVent BioPharma (AVBP) position steady in Q2 2026 at 24 shares worth $834. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

Parallel Advisors first reported a position in AVBP in Q4 2024 and has held it in 5 quarters since. The position peaked at $1.78K in Q2 2025. 41 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Parallel Advisors held 24 shares of ArriVent BioPharma worth $834 as of Q2 2026.
Parallel Advisors left its ArriVent BioPharma share count unchanged in Q2 2026.
ArriVent BioPharma made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3717 holding.
Parallel Advisors first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 5 quarters since.
Parallel Advisors's ArriVent BioPharma position peaked at $1.78K in Q2 2025.
41 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.